TrialDiabetes, obesity & metabolism2022

A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication.

Sérgio Vencio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.